Navigation Links
Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry

NEW YORK, June 14, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry


A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result of rising healthcare costs, healthcare budgets are being stretched.

Healthcare payers are also feeling the impact of the global economic downturn.

As a result, payers are introducing a number of cost-containment strategies as well as tougher regulatory measures

Features and benefits

* An overview of drivers of rising healthcare costs

* Review the impact of the global economic downturn on the healthcare and the pharmaceutical industry

* Assess the growing cost-containment and regulatory pressures facing pharma

* An overview of the impact of the patent expiries on pharma together with the industry's responses


Aging populations, the growing prevalence of chronic disease, greater use of expensive treatments, and expanding public healthcare coverage are stretching existing healthcare resources. As a result of rising unemployment, healthcare payers are also feeling the impact of the global economic downturn through reduced funding via taxation.

In response, payers are introducing a number of cost-containment strategies, such as reducing healthcare budgets and implementing pricing and reimbursement cuts, as well as bolstering generic uptake. These measures, together with the increasingly tough regulatory environment, all have a negative impact on the pharmaceutical industry.

Branded pharmaceutical companies are set to lose approximately $100bn in sales due to the patent cliff and the resultant generic erosion of branded sales during 2010–15 in the seven major markets, while the industry is also feeling the effects of the recent global economic downturn both directly and indirectly.

Your key questions answered

* Evaluate factors driving healthcare costs in the developed and emerging markets, and how the economic downturn has impacted the healthcare landscape

* Gain insight into the impact that the patent cliff as well as growing use of biosimilars will have on branded pharma sales out to 2015

* Review the growing cost-containment and regulatory measures facing pharma, as well as the industry's response to grow profitability going forward

Executive Summary

Strategic scoping and focus

Key findings


Demographic trends in the major developed and emerging markets

Aging patient populations

Growing prevalence of chronic diseases

Greater use of expensive treatments – pharmaceutical expenditure is increasing in all markets

Expanding pubic healthcare coverage


Impact of the economic downturn on both developed and emerging markets

Growing uninsured population – US patients are less able to cover the costs of healthcare, including pharmaceuticals

Government strategies to cut the budget deficit target healthcare and pharmaceutical expenditure


Government strategies to contain healthcare and pharma costs

Healthcare spending has slowed in several markets as governments bring in austerity measures

Pricing and reimbursement cuts were key elements included in austerity measures in many developed markets

Regulatory changes have a largely negative impact on pharma

Healthcare systems globally are converging toward a similar model

Driving generic uptake will create further savings


The patent cliff represents a major resistor to branded pharma growth

Branded pharma set to lose $82bn due to the patent cliff

Biosimilar uptake is set to accelerate


Pharma innovates, diversifies, and contains cost in order to grow profits

Pharma's strategic responses to drive sales and profitability

Innovation – pharma sharpens its focus on secondary care indications through high value biologic therapies

Diversification – growth in global markets will more than offset sales decline in the US

Cost-cutting – pharma cuts cost to increase margins

The impact of pharma's strategic responses on forecast sales during 2010–15


Publications and online articles

Datamonitor reports and products


Exchange rates used in this report

To order this report:

Managed care Industry: Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry

Managed care Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries
2. Reportlinker Adds Global Electrophysiology Mapping and Ablation Devices Industry
3. Reportlinker Adds Middle East And Africa Neurology Devices Market Outlook to 2017
4. Reportlinker Adds South and Central America Dental Devices Market Outlook to 2017
5. Reportlinker Adds Middle East and Africa Dental Devices Market Outlook to 2017
6. Reportlinker Adds Asia-Pacific Markets for Patient Monitoring Devices 2011
7. Reportlinker Adds European Markets for Hearing Aids and Audiology Devices 2011
8. Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Middle East and Africa ENT Devices Market Outlook to 2017
10. Reportlinker Adds China Medical Devices Industry - A Market Snapshot and Key Company Profiles
11. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Post Your Comments:
(Date:12/1/2015)... December 1, 2015 --> ... research report "Nucleic Acid Labeling Market by Product (Reagents ... Random Primer, In Vitro Transcription, Reverse Transcription, End Labeling), ... MarketsandMarkets, The global market is expected to reach USD ... 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , Dec. 01, 2015 ... announced the addition of the ... Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, ... report to their offering. --> ... addition of the "2016 Europe ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... Unified Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation ... deploy and support Cisco Unified Contact Center solutions targeted to the high-end enterprise ...
Breaking Medicine News(10 mins):